Healthy growth in key markets helped Dr Reddy’s Laboratories to post strong operating performance in the September quarter. Though Q2 numbers were lower on a year-on-year basis, the corresponding quarter last year had seen one-off gains. The reported numbers, however, came in ahead of analyst expectations. Improved traction in the US was evident from North America’s 28% growth, led by new products launches, increase in volumes of existing products, and a favorable forex rate. Gains on account of higher sales were partially offset by price erosion.